Chugai Pharmaceuticals develops and markets prescription products, non-prescription products including OTC drugs, nutritional supplements and diagnostic products. The company develops therapies for bone metabolism and blood disorders, cancer, infectious diseases and cardiovascular and brain diseases. The important products includes Alfarol® (alfacalcidol) a vitamin D3 analog for treating osteoporosis, Epogin® (epoetin beta) a recombinant human erythropoietin for treating anemia associated with chronic renal failure, Neutrogin® (lenograstim) a recombinant human granulocyte-colony stimulating factor (rG-CSF) for treating neutropenia associated with chemotherapy and Sigmart® (nicorandil) for treating angina. Roche owns about 50.1% of Chugai Pharmaceutical.